首页> 美国卫生研究院文献>other >A high-throughput screen for the engineered production of β-lactam antibiotics
【2h】

A high-throughput screen for the engineered production of β-lactam antibiotics

机译:高通量筛选的设计生产的β内酰胺类抗生素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

High-throughput screens and selections have had profound impact on our ability to engineer proteins possessing new, desired properties. These methods are especially useful when applied to the modification of existing enzymes to create natural and unnatural products. In an advance upon existing methods we developed a high-throughput, genetically-regulated screen for the in vivo production of β-lactam antibiotics using a green fluorescent protein (gfp) reporter. This assay proved reliable, sensitive and presents a dynamic range under which a wide array of β-lactam architectural sub-classes can be detected. Moreover, the graded response elicited in this assay can be used to rank mutant activity. The utility of this development was demonstrated in vivo and then applied to the first experimental investigation of a putative catalytic residue in carbapenem synthase (CarC). Information gained about the mutability of this residue defines one parameter for enzymatic activity and sets boundaries for future mechanistic and engineering efforts.
机译:高吞吐量屏幕和选择对我们的工程蛋白质的能力产生了深远的影响,具有具有新的,所需的性质的蛋白质。当应用于现有酶的修饰以产生自然和非自然产品时,这些方法特别有用。在现有方法之前,我们开发了使用绿色荧光蛋白(GFP)报告者体内生产β-内酰胺抗生素的高通量的遗传调节筛网。该试验证明可靠,敏感,并具有动态范围,可以检测到各种β-内酰胺架构子类。此外,在该测定中引发的分级响应可用于对突变活性进行排序。该开发的实用性在体内证实,然后应用于Carbapenem合成酶(CARC)中推定催化残基的第一次实验研究。对该残留物的可变性获得的信息定义了一种参数,用于酶活性,并为未来的机制和工程努力设定界限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号